Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been assigned a consensus recommendation of “Buy” from the sixteen research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, twelve have issued a buy rating and three have given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $32.5833.

Several analysts recently weighed in on DNLI shares. Wedbush dropped their target price on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Thursday, December 11th. JPMorgan Chase & Co. raised their price target on Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Stifel Nicolaus set a $37.00 price objective on Denali Therapeutics in a research note on Monday, November 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Denali Therapeutics in a research note on Monday, September 8th.

Denali Therapeutics Trading Up 0.6%

NASDAQ DNLI opened at $16.51 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.79 and a quick ratio of 9.79. The stock has a market capitalization of $2.42 billion, a P/E ratio of -5.67 and a beta of 1.05. The firm’s 50-day moving average is $17.30 and its two-hundred day moving average is $15.55. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $24.34.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.02. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.63) EPS. On average, sell-side analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current year.

Hedge Funds Weigh In On Denali Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Tudor Investment Corp ET AL lifted its stake in Denali Therapeutics by 1.7% in the third quarter. Tudor Investment Corp ET AL now owns 56,368 shares of the company’s stock worth $818,000 after acquiring an additional 920 shares during the last quarter. Hudson Bay Capital Management LP raised its holdings in shares of Denali Therapeutics by 5.2% in the 3rd quarter. Hudson Bay Capital Management LP now owns 305,000 shares of the company’s stock valued at $4,429,000 after purchasing an additional 15,000 shares in the last quarter. Cantor Fitzgerald L. P. acquired a new stake in shares of Denali Therapeutics in the 3rd quarter valued at $653,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Denali Therapeutics during the 3rd quarter worth $205,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Denali Therapeutics during the third quarter worth $667,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.